GM Clifford

M Rickenbach

S Franceschi

Infectious Agents and Cancer

English

null null

Crossref

BioMed CentralPage 1 of 1(page number not for citation purposes)Infectious Agents and CancerOpen AccessOral presentationInfluence of HIV-related immunodeficiency on the risk of hepatocellular carcinomaGM Clifford*1, M Rickenbach2, S Franceschi1 and the Swiss HIV Cohort StudyAddress: 1International Agency for Research on Cancer, Lyon, France and 2Coordination and Data Center, Swiss HIV Cohort Study, Lausanne, Switzerland* Corresponding author    ObjectiveTo investigate HIV-related immunodeficiency as a risk fac-tor for hepatocellular carcinoma (HCC) among personsinfected with HIV, whilst controlling for the effect of fre-quent co-infection with hepatitis C and hepatitis Bviruses.DesignA case-control study nested in the Swiss HIV Cohort Study(SHCS).MethodsTwenty-six HCC cases were identified in the SHCS orthrough linkage with Swiss Cancer Registries, and wereindividually matched to 251 controls by SHCS centre,gender, HIV-transmission category, age and year at enrol-ment. Odds ratios (OR) and corresponding confidenceintervals (CI) were estimated by conditional logisticregression.ResultsAll cases and 53 percent of controls (92% of controlsamong intravenous drug users [IDU]) were positive forhepatitis B superficial antigen (HBsAg) or antibodiesagainst HCV (anti-HCV). HCC cases included 14 IDU(three positive for HBsAg, 13 for anti-HCV), and 12 menhaving sex with men (MSM)/heterosexual/others (11 pos-itive for HBsAg, three for anti-HCV), revealing a strongrelationship between HIV transmission route and hepati-tis viral type. Latest CD4+ cell count was significantlyassociated with HCC (OR for lowest versus highest tertile= 4.26, 95% CI: 1.18–15.5). This effect was concentratedamong MSM/heterosexual/others (OR = 18.2, 95% CI:1.61–207) rather than IDU (OR = 1.79, 95% CI: 0.39–8.23). HAART use was not significantly associated withHCC risk (OR for ever versus never = 0.59, 95% CI: 0.18–1.91).ConclusionMore than CD4+ cell counts increased the risk for HCCamong persons infected with HIV, an effect that was par-ticularly evident for HBV-related HCC arising in non-IDUs.from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical ResearchBethesda, MD, USA. 6–7 October 2008Published: 17 June 2009Infectious Agents and Cancer 2009, 4(Suppl 2):O6 doi:10.1186/1750-9378-4-S2-O6<supplement> <title> <p>Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research</p> </title> <sponsor> <note>Publication of this supplement was made possible with support from the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health.</note> </sponsor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1750-9378-4-S2-full.pdf">here</a>.</note> url>http://www.biomedcentral.com/content/pdf/1750-9378-4-S2-info.pdf</url> </supplement>This abstract is available from: http://www.infectagentscancer.com/content/4/S2/O6© 2009 Clifford et al; licensee BioMed Central Ltd. 

Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

https://infectagentscancer.biomedcentral.com/track/pdf/10.1186/1750-9378-4-S2-O6?site=infectagentscancer.biomedcentral.com

Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

Abstract

Similar works

Full text

Available Versions

Crossref